DEFA14A: Enhabit Announces Preliminary Q2 2024 Results, Shows Business Stabilization

Enhabit, Inc. released unaudited preliminary results for Q2 2024, indicating business stabilization and progress in key operational areas.

Summary

• Enhabit, Inc. announced preliminary unaudited results for the second quarter ended June 30, 2024.
• Adjusted EBITDA is expected to be in the range of $24.5 million to $25.0 million.
• The company reduced bank debt by $15 million, including a $10 million payment on its revolving credit facility.
• 43% of non-Medicare visits are shifting to payor innovation contracts at improved rates, up from 38% in Q1 2024.
• Home health admissions increased by 6.4% year-over-year, driven by non-Medicare admissions.
• The hospice segment achieved monthly sequential growth in average daily census in June for the fifth consecutive month.
• The company is managing costs effectively, with home health cost per visit better than expected and hospice cost per day decreasing sequentially.
• The company plans to report actual second quarter 2024 financial results on Aug. 6, 2024, and host a webcast and conference call on Aug. 7, 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the reported business stabilization, debt reduction, and growth in key segments. However, the preliminary nature of the results and the inherent risks associated with forward-looking statements temper the overall sentiment.

Positives

• The company is showing signs of business stabilization and positioning for profitable growth.
• Debt reduction efforts are underway, with a $15 million reduction in bank debt.
• The shift towards payor innovation contracts is improving rates for non-Medicare visits.
• Home health admissions are increasing, particularly in the non-Medicare segment.
• The hospice segment is experiencing consistent growth in average daily census.
• Cost management initiatives are yielding positive results in both home health and hospice segments.

Risks

• Actual results may differ materially from preliminary results due to the completion of financial close procedures, final accounting adjustments, and other developments.
• The preliminary results are not necessarily indicative of future performance.
• Forward-looking statements are subject to risks and uncertainties, including regulatory changes, reimbursement rates, economic conditions, and the company's ability to execute its strategic plans.

Future Outlook

The company is on track to mark its third consecutive quarter of business stabilization and successfully positioning the company for profitable growth.

Management Comments

• The strong start to 2024 extended in Q2 as our teams successfully executed on our operational strategies.
• In our home health segment, our 6.4% year-over-year increase in admissions continues to be driven by non-Medicare admissions, and our teams are doing a good job managing our visits per episode and creating additional capacity for growth.
• In our hospice segment, we achieved monthly sequential growth in average daily census in June for the fifth consecutive month.
• Overall, the second quarter of 2024 is on track to mark Enhabit's third consecutive quarter of business stabilization and successfully positioning the Company for profitable growth.

Industry Context

The announcement reflects Enhabit's efforts to navigate the evolving home health and hospice landscape, focusing on operational efficiency, strategic growth in non-Medicare segments, and cost management. The shift towards payor innovation contracts aligns with industry trends towards value-based care.

Comparison to Industry Standards

• It is difficult to compare the results to industry standards without knowing the specific benchmarks for home health and hospice providers.
• However, the reported Adjusted EBITDA and debt reduction efforts can be compared to similar companies in the sector, such as Amedisys or LHC Group, once their Q2 results are released.
• The 6.4% increase in home health admissions and the growth in hospice census can be benchmarked against industry averages for patient volume growth.

Legal Proceedings

• The company is involved in a lawsuit, Enhabit, Inc. et al. v. Nautic Partners IX, L.P., et al., related to actions involving its former officers.

Stakeholder Impact

• Shareholders may view the preliminary results positively due to the signs of business stabilization and debt reduction.
• Employees may be encouraged by the company's progress and focus on growth.
• Patients should benefit from the company's efforts to expand access to home health and hospice services.
• Creditors may be reassured by the company's debt reduction efforts.

Next Steps

• The company plans to report actual second quarter 2024 financial results on Aug. 6, 2024.
• Enhabit will host a webcast and conference call on Aug. 7, 2024, to discuss the Q2 2024 results.

Key Dates

Keywords

Enhabit, Home Health, Hospice, Q2 2024, Preliminary Results, Adjusted EBITDA, Debt Reduction, Admissions, Census, Financial Results